Kymera Therapeutics Inc Revenue Growth Rates (KYMR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kymera Therapeutics Inc   (NASDAQ: KYMR)
 

KYMR's Revenue Growth by Quarter and Year

Kymera Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KYMR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 65.00
1st Quarter March 34.37
FY 99.37

KYMRs Annual Revenue
Kymera Therapeutics Inc 's Revenue in the fiscal year 2025 $ 39.21 millions
Kymera Therapeutics Inc 's Revenue in the fiscal year 2024 $ 47.07 millions
Kymera Therapeutics Inc 's Revenue in the fiscal year 2023 $ 78.59 millions
Kymera Therapeutics Inc 's Revenue in the fiscal year 2022 $ 46.83 millions
Kymera Therapeutics Inc 's Revenue in the fiscal year 2021 $ 72.83 millions




KYMR Revenue second quarter 2026 Y/Y Growth Comment
Kymera Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue surge of 466.2% year on year, to $ 65.00 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue growth. While Kymera Therapeutics Inc ' s Revenue doubling of 466.2% ranks overall at the positon no. 3452 in the second quarter 2026.


KYMR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -61.16 % -84.57 % 196.72 %
3rd Quarter September - -26.2 % -20.93 % -50.47 %
2nd Quarter June 466.2 % -55.24 % 55.36 % 43.44 %
1st Quarter March 55.52 % 114.77 % 8.66 % -1.56 %
FY   - -16.7 % -40.11 % -

Financial Statements
Kymera Therapeutics Inc 's second quarter 2026 Revenue $ 65.00 millions KYMR's Income Statement
Kymera Therapeutics Inc 's second quarter 2025 Revenue $ 11.48 millions Quarterly KYMR's Income Statement


KYMR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 3.99 % 97.59 % 912.47 %
3rd Quarter September - -75.96 % -85.42 % -71.35 %
2nd Quarter June 89.12 % -48.05 % 149.27 % 74.34 %
1st Quarter March 1097.56 % 199.05 % -78.51 % -41.33 %
FY (Year on Year)   - -16.7 % -40.11 % -


Back to KYMR Growth rate Comparisons >> Back to KYMR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #464
Overall #3452

Revenue Y/Y Growth Statistics
High Average Low
216.87 % 24.01 % -50.05 %
(Sep 30 2021)   (Sep 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #464
Overall #3452
Revenue Y/Y Growth Statistics
High Average Low
216.87 % 24.01 % -50.05 %
(Sep 30 2021)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Kymera Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1096.97 % 104.53 % -85.42 %
(Mar 31 2026)  


KYMR's II. Quarter Q/Q Revenue Comment
Kymera Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 89.12% quarter on quarter, to $ 65.00 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -48.05% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Kymera Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 144.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #46
Overall #144
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #46
Overall #144
Revenue Q/Q Growth Statistics
High Average Low
1096.97 % 104.53 % -85.42 %
(Mar 31 2026)  


KYMR's II. Quarter Q/Q Revenue Comment
Kymera Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 89.12% quarter on quarter, to $ 65.00 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -48.05% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Kymera Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 144.


Kymera Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 105.00 $ 51.48 $ 39.21 $ 43.73 $ 44.71
Y / Y Revenue Growth (TTM) 134.84 % -12.58 % -16.7 % -50.05 % -49.51 %
Year on Year Revenue Growth Overall Ranking # 3617 # 2773 # 2321 # 68 # 104
Seqeuential Revenue Change (TTM) 103.98 % 31.28 % -10.34 % -2.19 % -24.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 3452 # 505 # 2337 # 1820 # 876


Cumulative Revenue growth Comment
Kymera Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 134.84% year on year, to $ 105 millions if the fiscal year would have ended in Jun 30 2026.
Kymera Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 24.01% and higher than -12.58% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 103.98 % from $51.48 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 24.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 103.98 % increase from $51.48 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 496 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2773 to 3617.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 497
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
216.87 %
 24.01 %
-50.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 464
S&P 500 # 3452
Cumulative Revenue growth Comment
Kymera Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 134.84% year on year, to $ 105 millions if the fiscal year would have ended in Jun 30 2026.
Kymera Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 24.01% and higher than -12.58% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 103.98 % from $51.48 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 24.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 103.98 % increase from $51.48 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 496 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2773 to 3617.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 497
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
216.87 %
24.01 %
-50.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 464
S&P 500 # 3452




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KYMR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Abeona Therapeutics Inc 697.48%$ 697.477 millions
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions


About Kymera Therapeutics Inc Revenue Growth Rates (KYMR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kymera Therapeutics Inc (CIK 1815442).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-333849
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kymera Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.